U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07523867) titled 'Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study' on April 05.
Brief Summary: This study evaluates the safety of finerenone compared with alternate-day spironolactone in patients with heart failure and diabetic kidney disease at increased risk of hyperkalemia.
Patients with chronic kidney disease and heart failure often benefit from mineralocorticoid receptor antagonists, but their use is frequently limited by elevated potassium levels. Finerenone has been associated with a lower risk of hyperkalemia in clinical trials, but direct comparisons with spironolactone in high-risk patients are limited...